Vir Biotechnology company info

What does Vir Biotechnology do?
Vir Biotechnology (NASDAQ:VIR) is deeply invested in the research and development of treatments and therapies for serious infectious diseases such as hepatitis B, influenza A, and COVID-19, leveraging cutting-edge technologies to address global health challenges. Traded on the NASDAQ under the ticker symbol VIR, this bio-tech firm focuses on using immune programming to develop solutions for conditions that currently lack adequate treatments. With a commitment to improving patient outcomes, Vir's projects range from early to late-stage clinical trials, aiming not just to treat diseases but to fundamentally understand and manipulate the immune system's response to pathogens. Their objective is to lead the way in infectious disease treatment, pioneering future standards in therapeutics and preventative care.
Vir Biotechnology company media
Company Snapshot

Is Vir Biotechnology a public or private company?

key
Ownership
Public

How many people does Vir Biotechnology employ?

people
Employees
576

What sector is Vir Biotechnology in?

pie chart
Sector
Health Care

Where is the head office for Vir Biotechnology?

location pin
Head Office
San Francisco, United States

What year was Vir Biotechnology founded?

founded flag
Year Founded
2016
What does Vir Biotechnology specialise in?
/Therapeutic Antibodies /Chronic Infections /Pandemic Preparedness /Antiviral Treatments /Immunology Research /Vaccine Development

What are the products and/or services of Vir Biotechnology?

Overview of Vir Biotechnology offerings
Development and commercialization of therapies for the treatment of COVID-19, prioritizing a monoclonal antibody treatment designed to neutralize the virus.
Research on hepatitis B virus (HBV) treatments, focusing on functional cure strategies through a combination of therapeutic approaches.
Influenza treatments, including the development of monoclonal antibodies aimed at providing a functional cure or significant protection against flu viruses.
HIV cure projects, focusing on the development of broadly neutralizing antibodies aiming to contribute to cure strategies for HIV/AIDS.
Respiratory syncytial virus (RSV) treatment efforts, dedicated to creating monoclonal antibodies for the prevention and treatment of RSV infections.
Investment in novel platform technologies for identifying and developing antibodies against pathogens with pandemic potential, aiming to rapidly respond to emerging infectious diseases.

Who is in the executive team of Vir Biotechnology?

Vir Biotechnology leadership team
  • Dr. Ann M. Hanly Ph.D.
    Dr. Ann M. Hanly Ph.D.
    Executive VP & Chief Technology Officer
  • Dr. Marianne  De Backer M.B.A., M.Sc., Ph.D.
    Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
    CEO & Director
  • Dr. Klaus  Frueh Ph.D.
    Dr. Klaus Frueh Ph.D.
    Co-Founder & Scientific Advisor
  • Dr. Lawrence  Corey M.D.
    Dr. Lawrence Corey M.D.
    Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker M.D.
    Dr. Louis J. Picker M.D.
    Co-Founder & Scientific Advisor
  • Mr. Sung H. Lee
    Mr. Sung H. Lee
    Executive VP & CFO
  • Dr. Jennifer Eileen Towne Ph.D.
    Dr. Jennifer Eileen Towne Ph.D.
    Executive VP & Chief Scientific Officer
  • Ms. Heather Rowe Armstrong
    Ms. Heather Rowe Armstrong
    Vice President of Investor Relations